INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Nov 12, 2013
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director
Transactions
- Exercise/Conversion
Common Stock
2013-11-09+368→ 3,479 total - Exercise/Conversion
Restricted Stock Units
2013-11-09−368→ 1,103 total→ Common stock (368 underlying)
Holdings
- 5,938,890(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock upon vesting of the unit.
- [F2]On November 16, 2012, the reporting person was granted 2,942 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 12.5% of the shares underlying the RSUs, became vested on November 9, 2013, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on every subsequent three-month anniversary of such date through August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan.
- [F3]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.